The continued dilemma about the usage of hydroxychloroquine : Respite is in randomized control trials
| Errataetall: |
CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 99(2020) vom: 29. Okt., Seite 310-311 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malviya, Amit [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 21.10.2020 Date Revised 07.12.2022 published: Print-Electronic CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2020.07.054 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313139598 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313139598 | ||
| 003 | DE-627 | ||
| 005 | 20231225145927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.07.054 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1043.xml |
| 035 | |a (DE-627)NLM313139598 | ||
| 035 | |a (NLM)32738490 | ||
| 035 | |a (PII)S1201-9712(20)30601-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malviya, Amit |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The continued dilemma about the usage of hydroxychloroquine |b Respite is in randomized control trials |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2020 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Int J Infect Dis. 2020 Aug;97:396-403. - PMID 32623082 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Chloroquine | |
| 650 | 4 | |a Covid 19 | |
| 650 | 4 | |a Evidence | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Prophylaxis | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 99(2020) vom: 29. Okt., Seite 310-311 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2020 |g day:29 |g month:10 |g pages:310-311 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2020.07.054 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2020 |b 29 |c 10 |h 310-311 | ||